Glenmark Generics Incorporation, USA, a subsidiary of Glenmark Generics, has been granted final approval for two abbreviated new drug applications (ANDA) by the United States Food and Drug Administration (USFDA).
The approvals is for the oral contraceptive products Norethindrone and Ethinyl Estradiol (Alyacen 1/35) tablets USP, 1 mg/0.035 mg and Norethindrone and Ethinyl Estradiol (Alyacen 7/7/7) tablets USP, 0.5 mg/0.035 mg, 0.75 mg/0.035 mg and 1 mg/0.035 mg, the generic equivalents of Ortho-McNeil Janssen’s Ortho-Novum 1/35-28 tablets and Ortho-Novum 7/7/7-28 tablets, respectively.
Alyacen 1/35 and Alyacen 7/7/7 tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. According to IMS Health for the 12 month period ending September 2011, these products achieved total market sales of approximately $96 million.
With this, the company's current portfolio consists of 75 generic products authorized for distribution in the US market and 41 ANDA's filed with the USFDA pending approval.
Glenmark Generics (GGL) is a subsidiary of Glenmark Pharmaceuticals (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries.
Glenmark Pharmaceuticals, a leader among the emerging market companies in drug discovery and development and most of its active substances in the pipeline are first-in-Class. Glenmark’s achievements over the year include a major deal with Sanofi in Crohn's disease, completing Phase II trials of its first novel product, crofelemer and demonstrated higher sales and profit growth.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1854.15 |
| Dr. Reddys Lab | 1350.75 |
| Cipla | 1497.80 |
| Lupin | 2357.65 |
| Zydus Lifesciences | 1001.20 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
